One of Achillion's several HCV compounds in development is ACH-3102, a potent second generation NS5A inhibitor which Achillion discovered in 2011 and nominated as a clinical candidate that same year. Because of the synergy noted in vitro between NS5A inhibitors and NS3 protease inhibitors, Achillion is rapidly advancing ACH-3102 through preclinical development and IND-enabling studies. The Company expects to begin a Phase 1 first-in-man clinical trial evaluating ACH-3102 during the first half of 2012.
ACH-3102 Advantages:
Potency. ACH-3102 has demonstrated excellent potency against HCV RNA replication in all genotypes including genotype 1a and resistant mutations.
Combinability. ACH-3102 is highly effective in combination with other oral compounds being developed for the treatment of HCV, and is highly synergistic in vitro when combined with ACH-2684, a NS3 protease inhibitor, and ribavirin.
Specificity. ACH-3102 is highly specific for inhibition of NS5A protein with no inhibition of human proteins.
Pharmacokinetics. ACH-3102 is anticipated to be dosed once-daily.
Safety. To date ACH-3102 has demonstrated a good safety profile in preclinical studies.
